Wordt geladen...
Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors
BACKGROUND: Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally ad...
Bewaard in:
| Gepubliceerd in: | J Gastrointest Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
AME Publishing Company
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6657323/ https://ncbi.nlm.nih.gov/pubmed/31392048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.03.11 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|